Very interesting and novel work being done in the tumor vaccine field! #asco2024

Dr Ingr Svane: 👏🏿 great talk on the stunning response rates inpatients who received ODO+ PDL1 Vaccine w/ anti-PD1 in melanoma --> showed promising vaccine specific immunity based on neoantigens that are TME specific 🤩 --> randomized data TBD #ASCO24

Loving the people and the vibes at the #MedscapeFellow event! #ASCO24

Dr James Zhou (Stanford) starts the day off by talking about how prodictive and generative AI models are being used to transform cancer care. The future is bright! 🔆🔆 #ASCO24 #medsapefellows

Dr Jane Perlmutter just gave an interesting talk on the pt perspectives in AI. In general, pts feel that AI will make things better: from reducing medical errors to better inclusion in studies. However, the ethical concerns are real & should be addressed #ASCO24 #Medscapefellows

Multimodal AI can risk stratify breast cancer patients for distant metastasis using histopathological images +/- clinical data ( re Dr Daniel Kates-Harbeck) #ASCO24 #Medscapefellows

ADCs continue to be 🔥 in the oncologic therapeutic landscape. We now need to consider payload resistance in addn to others when deciding on next lines of therapy after progression on an ADC (re Dr Patricia LoRusso) #ASCO24 #Medscapefellows

Love sharing last night with our wonderful group of trainees & mentees, international collaborators, and UCSF Helen Diller Family Comprehensive Cancer Ctr faculty dedicated to mentoring the next gen of global leaders! 🙏🏽 Katherine Van Loon, MD, MPH for co-hosting! #GlobalCancer #GlobalOnc #DEIA #ASCO24 ASCO Rovika (Rovingaile Kriska) Ponce (she/her/siya) Bryan Lau

#ASCOLung Practice changing LAURA study of osimertinib post-chemoradiation in EGFR mut unresectable NSCLC #ASCO24 #LCSM

Thrilled to finally share our recent paper in Nature Cancer which characterizes the tumor immune microenvironment of microscopic residual HCC and identifies drivers of tumor recurrence!! So thankful to have been mentored by renumathyd and thankful for the whole team 🎉🎉🎉🎉🎉🎉

Getting ready for this interesting session on the first night of the annual ASCO conference! #MedscapeFellow #MedscapeOncology #ASCO2025

Interesting session! Key points ✨ 1) NTRK fusion:hidden unless you TEST! 2) Common in rare cancers but rare in common cancers 3) CR/PR rates> 70% in all cancers, min tox --> max QOL 4) Add 2nd line NTRKi for on target resistance 5) 👍🏿 CNS penetration! #MedscapeFellow #ASCO2025

A year ago vs today! It's been fun being in fellowship with the Medscape community! 🥰 I've enjoyed the educational programming this far ✨✨✨ #MedscapeFellow #MedscapeOncology #ASCO2025 Stacey L Hughes

Great session! Key points ✨ 1) Rapidly changing field! 2) For endometrial cancer, TEST TEST TEST: POLE, MMR, HRD, P53 status drives management. 3) Ovarian: adjuvant and maintenance tx driven by tumor genetics +grade/histo>>> hx cisplatin tx #MedscapeFellow Medscape Oncology #ASCO2025

As heme-onc fellows, we are often isolated in our programs and even our state. But we got an awesome opportunity to network with other fellows from programs across the country through the Medscape fellowship program! ✨✨ #MedscapeFellow #ASCO2025 Medscape Oncology

This to me is one of the most exciting studies presented at ASCO this year! #ASCO2025 #MedscapeFellow